BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts
Authors:
Open Access
- 30 April 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (13) , 1607-1613
Abstract
BAY 58-2667 (BAY-58) directly activates soluble guanylyl cyclase without tolerance in a nitric oxide (NO)-independent manner, and its haemodynamic effect is similar to that of nitroglycerin. We tested whether BAY-58 could make both rabbit and rat hearts resistant to infarction when given at the end of an ischaemic insult. All hearts were exposed to 30 min regional ischaemia followed by 120-(isolated hearts) or 180-(in situ hearts) min reperfusion. BAY-58 (1–50 nM) infused for 60 min starting 5 min before reperfusion significantly reduced infarction from 33.0 ± 3.2% in control isolated rabbit hearts to 9.5–12.7% (P < 0.05). In a more clinically relevant in situ rabbit model, infarct size was similarly reduced with a loading dose of 53.6 µg/kg followed by a 60 min infusion of 1.25 µg/kg/min (41.1 ± 3.1% infarction in control hearts to 16.0 ± 4.4% in treated hearts, P < 0.05). BAY-58 similarly decreased infarction in the isolated rat heart, and protection was abolished by co-treatment with a protein kinase G (PKG) antagonist, or a mitochondrial KATP channel antagonist. Conversely, Nω-nitro-L-arginine-methyl-ester-hydrochloride, a NO-synthase inhibitor, failed to block BAY-58's ability to decrease infarction, consistent with the latter's putative NO-independent activation of PKG. Finally, BAY-58 increased myocardial cGMP content in reperfused hearts while cAMP was unchanged. When applied at reperfusion, BAY-58 is an effective cardioprotective agent with a mechanism similar to that of ischaemic pre-conditioning and, hence, should be a candidate for treatment of acute myocardial infarction in man.Keywords
This publication has 23 references indexed in Scilit:
- Vardenafil protects isolated rat hearts at reperfusion dependent on GC and PKGBritish Journal of Pharmacology, 2008
- Mapping Preconditioning's Signaling PathwaysAnnals of the New York Academy of Sciences, 2008
- Cyclic GMP and protein kinase‐G in myocardial ischaemia‐reperfusion: opportunities and obstacles for survival signalingBritish Journal of Pharmacology, 2007
- B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heartBasic Research in Cardiology, 2007
- Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial KATP channels when administered at reperfusion following ischemia in rabbitsJournal of Molecular and Cellular Cardiology, 2007
- Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit heartsBasic Research in Cardiology, 2006
- Postconditioning the Human HeartCirculation, 2005
- Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotectionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004
- Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioningAmerican Journal of Physiology-Heart and Circulatory Physiology, 2003
- Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.Circulation, 1986